Madrid – Spain – October 29 – November 1, 2024
CTAD 2024
The 17th Clinical Trials on Alzheimer’s Disease conference (CTAD), will be held in Madrid (Spain) on October 29 – November 1, 2024.
This past October in Boston, USA, CTAD 2023 attracted over 2,250 international leaders to discuss the future of Alzheimer’s Disease clinical research
The year 2023 has seen breakthrough advances with the market authorization of two anti-amyloid treatments, the implementation of blood biomarkers in clinical practice and trials, as well as exciting readouts from Phase 1 and Phase 2 AD clinical trials
At CTAD 2024 the scientific program will again focus on bringing thought-provoking roundtable and symposia on the latest advances in AD clinical research, bringing together renowned clinicians and leaders from key research centers, academia, patient coalition and pharmaceutical companies.
CTAD is also committed to exploring new avenues beyond amyloid-clearing treatments including disease-modifying agents, gene therapy, vaccines and multimodal interventions.
The CTAD scientific program is based on a strict peer-review abstract selection process. CTAD 2024 is a great opportunity for clinical teams around the world to showcase their work in AD clinical trials.
Proceedings from CTAD are published in the Journal of Prevention and Alzheimer’s Disease (Springer Nature Company)
For more information please visit our website www.ctad-alzheimer.com or contact the CTAD 2024 secretariat at ctad@ant-congres.com
CTAD 2024 Scientific Committee
President of the CTAD24 Scientific Committee: Merce Boada
- Susan ABUSHAKRA (San Francisco, USA)
- Paul AISEN (San Diego, USA)
- Rebecca E. AMARIGLIO (Boston, USA)
- Randall J. BATEMAN (St. Louis, USA)
- Kaj BLENNOW (Molndal, Sweden)
- Merce BOADA (Barcelona, Spain)
- Marc CANTILLON (Livingston, USA)
- Maria CARRILLO (Chicago, USA)
- Suzanne CRAFT (Winston-Salem, USA)
- Steven DEKOSKY (Miami, USA)
- Michael C DONOHUE (San Diego, USA)
- Rachelle DOODY (Basel, Switzerland)
- Bruno DUBOIS (Paris, France)
- Howard FELDMAN (San Diego, USA)
- Howard FILLIT (New York, USA)
- Nick FOX (London, UK)
- Giovanni B. FRISONI (Brescia, Italy)
- Serge GAUTHIER (Montreal, Canada)
- Michael GRUNDMANN (San Diego, USA)
- Harald HAMPEL (Woodcliff Lake, USA)
- Oskar HANSSON (Lund, Sweden)
- Tobias HARTMANN (Homburg, Germany)
- Takeshi IWATSUBO (Tokyo, Japan)
- Frank JESSEN (Cologne, Germany)
- Ara KHACHATURIAN (Washington DC, USA)
- Zaven KHACHATURIAN (Washington DC, USA)
- Yan LI (St. Louis, USA)
- Jorge J. LLIBRE GUERRA (St. Louis, USA)
- Constantine G. LYKETSOS (Baltimore, USA)
- Gad A. MARSHALL (Boston, USA)
- Lefkos T. MIDDLETON (London, UK)
- José Luis MOLINUEVO (Barcelona, Spain)
- Ronald PETERSEN (Minnesota, USA)
- Michael S. RAFII (San Diego, USA)
- Rema RAMAN (San Diego, USA)
- Craig W. RITCHIE (Edinburgh, UK)
- Robert RISSMAN (San Diego, USA)
- Marwan SABBAGH (Las Vegas, USA)
- Stephen SALLOWAY (Providence, USA)
- Rachel SCHINDLER (New York, USA)
- Philip SCHELTENS (Amsterdam, NL)
- Lon SCHNEIDER (Los Angeles, USA)
- Eric SIEMERS (Philadelphia, USA)
- Yong SHEN (Heife, China)
- Jiong SHI (Las Vegas, USA)
- Reisa SPERLING (Boston, USA)
- Yaakov STERN (New York, USA)
- Jacques TOUCHON (Montpellier, France)
- Christopher H. VAN DYCK (New Haven, USA)
- Bruno VELLAS (Toulouse, France)
- Michael W. WEINER (San Francisco, USA)
- Bengt WINBLAD (Stockholm, Sweden)
- Jin-Tai YU (Shanghai, China)
|
|
